Literature DB >> 24778117

Synergistic effects of Clostridium perfringens enterotoxin and beta toxin in rabbit small intestinal loops.

Menglin Ma1, Abhijit Gurjar2, James R Theoret1, Jorge P Garcia3, Juliann Beingesser3, John C Freedman1, Derek J Fisher4, Bruce A McClane1, Francisco A Uzal5.   

Abstract

The ability of Clostridium perfringens type C to cause human enteritis necroticans (EN) is attributed to beta toxin (CPB). However, many EN strains also express C. perfringens enterotoxin (CPE), suggesting that CPE could be another contributor to EN. Supporting this possibility, lysate supernatants from modified Duncan-Strong sporulation (MDS) medium cultures of three CPE-positive type C EN strains caused enteropathogenic effects in rabbit small intestinal loops, which is significant since CPE is produced only during sporulation and since C. perfringens can sporulate in the intestines. Consequently, CPE and CPB contributions to the enteropathogenic effects of MDS lysate supernatants of CPE-positive type C EN strain CN3758 were evaluated using isogenic cpb and cpe null mutants. While supernatants of wild-type CN3758 MDS lysates induced significant hemorrhagic lesions and luminal fluid accumulation, MDS lysate supernatants of the cpb and cpe mutants caused neither significant damage nor fluid accumulation. This attenuation was attributable to inactivating these toxin genes since complementing the cpe mutant or reversing the cpb mutation restored the enteropathogenic effects of MDS lysate supernatants. Confirming that both CPB and CPE are needed for the enteropathogenic effects of CN3758 MDS lysate supernatants, purified CPB and CPE at the same concentrations found in CN3758 MDS lysates also acted together synergistically in rabbit small intestinal loops; however, only higher doses of either purified toxin independently caused enteropathogenic effects. These findings provide the first evidence for potential synergistic toxin interactions during C. perfringens intestinal infections and support a possible role for CPE, as well as CPB, in some EN cases.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24778117      PMCID: PMC4097624          DOI: 10.1128/IAI.01848-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Clostridium perfringens beta-toxin forms multimeric transmembrane pores in human endothelial cells.

Authors:  V Steinthorsdottir; H Halldórsson; O S Andrésson
Journal:  Microb Pathog       Date:  2000-01       Impact factor: 3.738

2.  Genotypic and phenotypic characterization of Clostridium perfringens isolates from Darmbrand cases in post-World War II Germany.

Authors:  Menglin Ma; Jihong Li; Bruce A McClane
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

3.  The effect of Clostridium perfringens type C strain CN3685 and its isogenic beta toxin null mutant in goats.

Authors:  J P Garcia; J Beingesser; D J Fisher; S Sayeed; B A McClane; H Posthaus; F A Uzal
Journal:  Vet Microbiol       Date:  2012-01-11       Impact factor: 3.293

4.  Evidence that the Agr-like quorum sensing system regulates the toxin production, cytotoxicity and pathogenicity of Clostridium perfringens type C isolate CN3685.

Authors:  Jorge E Vidal; Menglin Ma; Julian Saputo; Jorge Garcia; Francisco A Uzal; Bruce A McClane
Journal:  Mol Microbiol       Date:  2011-12-07       Impact factor: 3.501

5.  Enteritis necroticans (pigbel) in a diabetic child.

Authors:  T M Petrillo; C M Beck-Sagué; J G Songer; C Abramowsky; J D Fortenberry; L Meacham; A G Dean; H Lee; D M Bueschel; S R Nesheim
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

6.  Synergistic effects of alpha-toxin and perfringolysin O in Clostridium perfringens-mediated gas gangrene.

Authors:  M M Awad; D M Ellemor; R L Boyd; J J Emmins; J I Rood
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 7.  Toxin plasmids of Clostridium perfringens.

Authors:  Jihong Li; Vicki Adams; Trudi L Bannam; Kazuaki Miyamoto; Jorge P Garcia; Francisco A Uzal; Julian I Rood; Bruce A McClane
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

8.  Epsilon toxin is essential for the virulence of Clostridium perfringens type D infection in sheep, goats, and mice.

Authors:  J P Garcia; V Adams; J Beingesser; M L Hughes; R Poon; D Lyras; A Hill; B A McClane; J I Rood; F A Uzal
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

9.  Clostridium perfringens beta-toxin induces necrostatin-inhibitable, calpain-dependent necrosis in primary porcine endothelial cells.

Authors:  Delphine Autheman; Marianne Wyder; Michel Popoff; Katharina D'Herde; Stephan Christen; Horst Posthaus
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

10.  The synergistic necrohemorrhagic action of Clostridium perfringens perfringolysin and alpha toxin in the bovine intestine and against bovine endothelial cells.

Authors:  Stefanie Verherstraeten; Evy Goossens; Bonnie Valgaeren; Bart Pardon; Leen Timbermont; Karen Vermeulen; Stijn Schauvliege; Freddy Haesebrouck; Richard Ducatelle; Piet Deprez; Filip Van Immerseel
Journal:  Vet Res       Date:  2013-06-19       Impact factor: 3.683

View more
  23 in total

Review 1.  Comparative pathogenesis of enteric clostridial infections in humans and animals.

Authors:  Francisco A Uzal; Mauricio A Navarro; Jihong Li; John C Freedman; Archana Shrestha; Bruce A McClane
Journal:  Anaerobe       Date:  2018-06-05       Impact factor: 3.331

2.  A synthetic peptide corresponding to the extracellular loop 2 region of claudin-4 protects against Clostridium perfringens enterotoxin in vitro and in vivo.

Authors:  Archana Shrestha; Susan L Robertson; Jorge Garcia; Juliann Beingasser; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Characterization of Clostridium perfringens TpeL toxin gene carriage, production, cytotoxic contributions, and trypsin sensitivity.

Authors:  Jianming Chen; Bruce A McClane
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

4.  Native or Proteolytically Activated NanI Sialidase Enhances the Binding and Cytotoxic Activity of Clostridium perfringens Enterotoxin and Beta Toxin.

Authors:  James R Theoret; Jihong Li; Mauricio A Navarro; Jorge P Garcia; Francisco A Uzal; Bruce A McClane
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

5.  Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease.

Authors:  Jihong Li; Bruce A McClane
Journal:  Infect Immun       Date:  2014-08-18       Impact factor: 3.441

6.  NanR Regulates nanI Sialidase Expression by Clostridium perfringens F4969, a Human Enteropathogenic Strain.

Authors:  Jihong Li; Daniel R Evans; John C Freedman; Bruce A McClane
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

Review 7.  The interaction of Clostridium perfringens enterotoxin with receptor claudins.

Authors:  Archana Shrestha; Francisco A Uzal; Bruce A McClane
Journal:  Anaerobe       Date:  2016-04-16       Impact factor: 3.331

8.  NanI Sialidase, CcpA, and CodY Work Together To Regulate Epsilon Toxin Production by Clostridium perfringens Type D Strain CN3718.

Authors:  Jihong Li; John C Freedman; Bruce A McClane
Journal:  J Bacteriol       Date:  2015-08-10       Impact factor: 3.490

Review 9.  Clostridium perfringens type A-E toxin plasmids.

Authors:  John C Freedman; James R Theoret; Jessica A Wisniewski; Francisco A Uzal; Julian I Rood; Bruce A McClane
Journal:  Res Microbiol       Date:  2014-10-02       Impact factor: 3.992

Review 10.  NetF-producing Clostridium perfringens and its associated diseases in dogs and foals.

Authors:  Iman Mehdizadeh Gohari; Stefan Unterer; Ashley E Whitehead; John F Prescott
Journal:  J Vet Diagn Invest       Date:  2020-02-21       Impact factor: 1.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.